GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (NYSE:NVO) » Definitions » 3-Year FCF Growth Rate

Novo Nordisk A/S (Novo Nordisk A/S) 3-Year FCF Growth Rate : 34.60% (As of Dec. 2023)


View and export this data going back to 1981. Start your Free Trial

What is Novo Nordisk A/S 3-Year FCF Growth Rate?

Novo Nordisk A/S's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.23.

During the past 12 months, Novo Nordisk A/S's average Free Cash Flow per Share Growth Rate was 10.40% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was 34.60% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 20.90% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 11.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Novo Nordisk A/S was 130.30% per year. The lowest was -51.70% per year. And the median was 22.00% per year.


Competitive Comparison of Novo Nordisk A/S's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Novo Nordisk A/S's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Nordisk A/S's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novo Nordisk A/S's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Novo Nordisk A/S's 3-Year FCF Growth Rate falls into.



Novo Nordisk A/S 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Novo Nordisk A/S  (NYSE:NVO) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Novo Nordisk A/S 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Nordisk A/S (Novo Nordisk A/S) Business Description

Address
Novo Alle 1, Bagsvaerd, DNK, DK-2880
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.